**Medical cannabis products under state licenses and FDA-approved formulations moved to Schedule III in April 2026 via DOJ order, while a separate expedited DEA administrative hearing addressed broader rescheduling of all marijuana from Schedule I.** That hearing ran from June 29 to July 15, 2026, with the DEA presenting evidence supporting a currently accepted medical use and advocating the Schedule III change. Post-hearing briefs are due August 17, after which the administrative law judge will issue a recommendation; the DEA Administrator then decides on final rulemaking. No statutory deadline governs the remaining steps, so timelines could extend into late 2026 or beyond, subject to possible legal challenges or procedural extensions. These developments shape trader views on resolution timing for any broader federal rescheduling outcome.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert$796,389 Vol.
31. März 2026
30. September
49%
31. Dezember
27%
$796,389 Vol.
30. September
$0 Vol.
49%
31. Dezember
$186,818 Vol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Medical cannabis products under state licenses and FDA-approved formulations moved to Schedule III in April 2026 via DOJ order, while a separate expedited DEA administrative hearing addressed broader rescheduling of all marijuana from Schedule I.**
That hearing ran from June 29 to July 15, 2026, with the DEA presenting evidence supporting a currently accepted medical use and advocating the Schedule III change. Post-hearing briefs are due August 17, after which the administrative law judge will issue a recommendation; the DEA Administrator then decides on final rulemaking. No statutory deadline governs the remaining steps, so timelines could extend into late 2026 or beyond, subject to possible legal challenges or procedural extensions. These developments shape trader views on resolution timing for any broader federal rescheduling outcome.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Markt eröffnet: Feb 7, 2026, 5:04 PM ET
Volumen
$796,389Enddatum
31. März 2026Markt eröffnet
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Medical cannabis products under state licenses and FDA-approved formulations moved to Schedule III in April 2026 via DOJ order, while a separate expedited DEA administrative hearing addressed broader rescheduling of all marijuana from Schedule I.**
That hearing ran from June 29 to July 15, 2026, with the DEA presenting evidence supporting a currently accepted medical use and advocating the Schedule III change. Post-hearing briefs are due August 17, after which the administrative law judge will issue a recommendation; the DEA Administrator then decides on final rulemaking. No statutory deadline governs the remaining steps, so timelines could extend into late 2026 or beyond, subject to possible legal challenges or procedural extensions. These developments shape trader views on resolution timing for any broader federal rescheduling outcome.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volumen
$796,389Enddatum
31. März 2026Markt eröffnet
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Medical cannabis products under state licenses and FDA-approved formulations moved to Schedule III in April 2026 via DOJ order, while a separate expedited DEA administrative hearing addressed broader rescheduling of all marijuana from Schedule I.** That hearing ran from June 29 to July 15, 2026, with the DEA presenting evidence supporting a currently accepted medical use and advocating the Schedule III change. Post-hearing briefs are due August 17, after which the administrative law judge will issue a recommendation; the DEA Administrator then decides on final rulemaking. No statutory deadline governs the remaining steps, so timelines could extend into late 2026 or beyond, subject to possible legal challenges or procedural extensions. These developments shape trader views on resolution timing for any broader federal rescheduling outcome.
Experimentelle KI-generierte Zusammenfassung mit Polymarket-Daten. Dies ist keine Handelsberatung und spielt keine Rolle bei der Auflösung dieses Marktes. · Aktualisiert
Vorsicht bei externen Links.
Vorsicht bei externen Links.
Häufig gestellte Fragen